Home
overview
As pharmaceutical companies continually strive to find new and evolving ways to combat neuropathic and neurological pain, The SMi Group’s 8th Annual Pain Therapeutics Conference once again showcases the new advances within the pharmaceutical industry.

Listen to case studies on novel targets for effective pain relief such as ion channels, CB2 receptors and the purinergic cascade and explore revolutionary strategies for confronting neuropathic pain.

Senior representatives from the top 10 Pharmaceutical Companies together with those from pharmaceutical companies that specialise in pain medication will deliver a series of specialised presentations detailing the discoveries and advances they have made over the last 12 months

The conference will be delivered by an excellent panel of speakers, including:
  • Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories
  • Dr Linda Surh, Director, CEDD Global Regulatory Affairs, GlaxoSmithKline
  • Dr Keith Bley, Senior Vice President, Nonclinical R&D, NeurogesX Inc
  • Dr Shimon Amselem, Vice President, Pharmaceutical Development, Pharmos Ltd
  • Professor Theo Meert, Senior Research Fellow, Therapeutics Area Leader & Biology Head,  CNS, Pain & Neurology, Johnson & Johnson
  • Dr Liza Leventhal, Principal Research Scientist 1, Neuroscience Discovery Research, Wyeth
  • Dr Steve England, Associate Research Fellow, Discovery Biology, Pfizer
  • Dr John Connell, Director, Clinical Pharmacodynamics & Project Management, Icon Development Solutions
  • Dr Emanuele Sher, Research Advisor, Pain/Migraine Team, Eli Lilly and Company
  • Roland Kozlowski, Chief Executive Officer, Lectus Therapeutics
  • Dr Edward Kaftan, Principal Research Scientist, Wyeth
  • Dr Peter Schafer, Director, Biology, Drug Discovery, Celgene Corporation
  • Dr John Hutchinson, Development Director and Board Member, Vernalis
  • Dr Helmut Buschman, Research Director, Laboratorios Dr. Esteve   
  • Andrew Sutton, Medical Director, Guildford Clinical Pharmacology
The continual success of The SMi Group’s Pain Therapeutics Conference stands as proof of its reputation as the leading conference in the field. With this year's promising to be the most successful, attendance is compulsory in order to keep abreast of developments in this ever-evolving industry.

Conference programme

8:30 Registration & Coffee

9:00 Chairperson's Opening Remarks

Dr Liza Leventhal

Dr Liza Leventhal, Principal Scientist 1, Wyeth Research

9:10 TRPV1 AGONIST APPROACHES TO LOCALIZED MANAGEMENT OF CHRONIC PAIN

Dr Keith Bley

Dr Keith Bley, Senior Vice President, Nonclinical R & D, Neurogesx Inc

·          Bases of nociceptor overactivity
·          Expression of TRPV1 in hyperactive nociceptors
·          Agonist-induced desensitization
·          Phase 2 clinical data for nociceptive pain
·          Phase 3 clinical data for neuropathic pain

9:50 CANNABINOR, A CB2 SELECTIVE SYNTHETIC CANNABINOID AGONIST FOR THE TREATMENT OF CHRONIC PAIN

Dr Shimon Amselem

Dr Shimon Amselem, Vice President, Pharmaceutical Development, Pharmos Ltd.

·          CB2 receptors as drug targets for neuropathic and chronic pain
·          Rational drug design of CB2 agonists
·          CB receptor binding affinity and selectivity
·          Pharmacological efficacy in animal models
·          Pharmaceutical development
Human trials with Cannabinor

10:30 Morning Coffee

11:00 NOVEL APPROACHES TO PAIN MEASUREMENTS IN RODENTS

·          Brief overview of traditional methods for evaluating pain in preclinical models
·          Introduction to alternative approaches for evaluating pain in preclinical models
·          Review of studies evaluating gait analysis in preclinical pain models
·          Alternative approaches and endpoints
·          Future directions
Dr Liza Leventhal

Dr Liza Leventhal, Principal Scientist 1, Wyeth Research

11:40 SMALL MOLECULE INHIBITORS OF Kv1.X/Kvß CHANNEL SUBUNIT

Roland Kozlowski

Roland Kozlowski, Chief Executive Officer , Lectus Therapeutics

·          Kv channels as targets for the treatment of pain
·          Kv1.x/Kvß LEPTICS® assay development and hit identification
·          In vitro electrophysiological characterisation of novel inhibitors of
Kv1.x/Kvß subunits in rat DRGs
·          In vivo evaluation of novel inhibitors of Kv1.x/Kvß subunits in models
of inflammatory and neuropathic hyperalgesia

12:20 Networking Lunch

13:50 ENGAGING THE REGULATORY AUTHORITIES WITH EMERGING BIOMARKERS: NEW WHYS AND WAYS

Dr Linda Surh

Dr Linda Surh, Director, CEDD Global Regulatory Affairs , GlaxoSmithKline

·          Drivers for biomarkers in the industry
·          Some working definitions and terms of engagement
·          Application of biomarkers across the pipeline, from imaging to systemic biomarkers
·          Biomarker-specific considerations with regulatory authorities in the US and EU 

14:30 ION CHANNELS, CAN THEY PROVIDE NEW TARGETS FOR EFFECTIVE PAIN RELIEF?

Dr Steve England

Dr Steve England, Associate Research Fellow, Discovery Biology, Pfizer

·          Voltage-gated sodium channels and what human genetic data tells us
·          Calcium Channels; can we improve on Ziconotide?
·          Ligand-gated channels; which are the most likely winners?
·          Emerging ion channel targets

15:10 Afternoon Tea

15:40 THE PURINERGIC CASCADE AS TARGETS FOR PAIN TREATMENT

Professor Theo Meert

Professor Theo Meert, Senior Research Fellow, Therapeutic Area Leader & Biology Head, CNS, Pain & Neurology, Johnson & Johnson

·          The role of adenosine in pain: P1 receptors and adenosine modulation
·          The role of P2X
The role of P2Y

16:20 SOME COMPELLING REASONS TO MEASURE MOODS DURING CHRONIC PAIN STUDIES

Andrew Sutton

Andrew Sutton, Medical Director, Guildford Clinical Pharmacology Ltd (GCPL)

  • Chronic pain makes people angry, sad, fatigued and irritable
  • These moods can be measured more reliably than pain itself
  • They are risk factors for cardiovascular events such as seen in the Vioxx study
  • Pain may decrease but if these moods do not, the risks remain.
  • Doing so improves: patient selection and compliance, dose efficacy monitoring, data variance & trial sensitivity
  • It demonstrates a quality of life advantage for the product.
  • 17:00 Chairperson’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr James Sullivan

    Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories

    9:10 CASE STUDY: ABBOTT’S NEURONAL NICOTINIC RECEPTOR PROGRAMME

    Dr James Sullivan

    Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories

    9:50 ACTIVATING CHOLINERGIC NICOTINIC RECEPTORS, GROUNDBREAKING APPROACHES TO NEUROPATHIC PAIN

    Dr Emanuele Sher

    Dr Emanuele Sher, Research Advisor, Pain/Migraine Team, Eli Lilly & Company

    ·          Inducing antinociception by the activation of nicotinic receptors by the endogenous neurotransmitter acetylcholine or exogenous agonists
    ·          The efficacy of nicotinic agonists shown in preclinical models of inflammatory and neuropathic pain
    ·          Suggestions of how this efficacy can be achieved in man
    ·          The preclusion of prior further development due to poor margin of safety
    ·          Achieving a better margin of safety by activating nicotinic receptors in the CNS without activating peripheral nicotinic receptors

    10:30 Morning Coffee

    11:00 NOVEL APPROACHES TO INFLAMMATORY AND NEUROPATHIC PAIN

    Dr Peter Schafer

    Dr Peter Schafer, Director, Biology, Drug Discovery, Celgene Corporation

    ·          Rationale for use of immunomodulatory agents (IMiDs®) in pain
    ·          Preclinical pharmacology of thalidomide and lenalidomide
    ·          Clinical studies in complex regional pain syndrome
    ·          Implications for future research and therapeutics

    11:40 DEVELOPMENT AND VALIDATION OF A VOLUNTEER MODEL OF NEUROPATHIC PAIN

    ·          What clinical end points are appropriate for healthy volunteers?
    ·          selection of a model
    ·          validation and bench-marking of a model
    ·          Can a healthy volunteer model predict clinical efficacy?
    Dr John Connell

    Dr John Connell, Director, Clinical Pharmacodynamics & Project Management, Icon Development Solutions

    12:20 Networking Lunch

    13:50 TARGETING SIGMA RECEPTORS AS A NEW THERAPEUTIC STRATEGY FOR NEUROPATHIC PAIN

    Dr Helmut Buschmann

    Dr Helmut Buschmann, Research Director, Laboratorios Dr. Esteve

    ·          How Sigma 1 receptor knockout mice do not develop allodynic behaviours after sciatic nerve lesions are induced
    ·          Spinal cords from mice lacking Sigma 1 receptors show reduced wind-up amplification
    ·          Neuropathic pain behaviours in wild-type animals are inhibited by new and selective Sigma 1 receptor antagonists
    ·          Medicinal chemistry approaches for discovery and development of highly selective Sigma receptor ligands

    14:30 DEFINING THE ROLE OF MrgD IN PAIN

    Dr Edward Kaftan

    Dr Edward Kaftan, Principal Research Scientist, Wyeth

    15:10 TRIPTANS IN THE MANAGEMENT OF MIGRAINES AND OTHER HEADACHE DISORDERS

    ·          Review of the pharmacology of triptans
    ·          Review of recent data relevant to migraine management
    ·          Efficacy and safety of the triptans in migraine treatment
    ·          Menstrual migraine prevention with frovatriptan
    ·          Triptans and management of other headaches
    Dr Stephen Pawsey

    Dr Stephen Pawsey, Director, Medical Affairs, Vernalis

    John Hutchinson

    John Hutchinson, Development Director and Board Member, Vernalis

    15:50 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    The Critical Path in the Discovery of New Pain Therapeutics
    Workshop

    The Critical Path in the Discovery of New Pain Therapeutics

    Crowne Plaza Hotel - The City
    13th June 2007
    London, United Kingdom

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.